Table 3.

Comparative univariate and multivariate analyses for bladder-recurrence free survival in multifocal UTUC patients.

	Univariate analysis		Multivariate analysis
	HR (95% CI)	p value	HR (95% CI)	p value
Age		0.014*		0.014*
< 67.7	1		1
≥ 67.7	1.400 (1.070, 1.832)		1.405 (1.071, 1.843)
Gender		0.001**		0.020*
Female	1		1
Male	1.593 (1.219, 2.081)		1.387 (1.053, 1.826)
Coronary artery disease		0.401
No	1
Yes	1.218 (0.769, 1.930)
Hypertension		0.191
No	1
Yes	1.195 (0.915, 1.561)
ESRD on dialysis		0.581
No	1
Yes	0.904 (0.632, 1.293)
Diabetes mellitus		0.258
No	1
Yes	1.192 (0.879, 1.616)
Gout		< 0.001**		< 0.001**
No	1		1
Yes	3.082 (1.849, 5.136)		3.107 (1.827, 5.284)
Non-UC malignancy		0.022*		0.039*
No	1		1
Yes	1.565 (1.068, 2.294)		1.507 (1.022, 2.222)
History of bladder tumor		0.002**		0.002**
No	1		1
Yes	1.531 (1.172, 2.000)		1.571 (1.182, 2.088)
Tumor grade		0.601
Low grade	1
High grade	1.109 (0.754, 1.631)
Pathological T stage		0.508
pTa/pTis/pT1	1
pT2-4	1.096 (0.836, 1.437)
Pathological N stage		0.963
pN0	1
pNx	1.068 (0.771, 1.478)	0.694
pN +	0.879 (0.431, 1.794)	0.723
Histologic variant		0.108
No	1
Yes	0.651 (0.385, 1.100)
Carcinoma in situ		0.811
No	1
Yes	1.042 (0.742, 1.465)
Lymphovascular invasion		0.381
No	1
Yes	1.153 (0.838, 1.587)
Tumor necrosis		0.896
No	1
Yes	1.024 (0.719, 1.459)
Tumor distribution		0.046*		0.020*
Multiple RPTs	1		1
Multiple UTs	1.460 (0.979, 2.177)	0.064	1.371 (0.916, 2.053)	0.126
Synchronous RPT and UT	1.461 (1.034, 2.064)	0.032*	1.526 (1.077, 2.164)	0.018*

RPTs, renal pelvic tumors; UTs, ureteral tumors; ESRD, end-stage renal disease; UC, urothelial carcinoma; CI, confidence; HR, hazard ratio.

* < 0.05; ** < 0.01.